Mark D. Pegram, MD

Articles

Optimizing Management of HR+/HER2- BC: Future Directions in Care

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Considerations for Use of ADCs in HER2-Low Breast Cancer

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

Recurrence Patterns in Early-Stage HR+ Breast Cancer

August 12th 2022

Drs Mark Pegram and Lee Schwartzberg examine late recurrence patterns in patients with HR+ breast cancer.

Updated Guidelines for the Management of HR+ Breast Cancer

August 12th 2022

Experts highlight some important and surprising updates in the ASCO guidelines for the management of HR+ breast cancer.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Measuring Ki-67 Levels to Inform HR+ Breast Cancer Treatment

August 5th 2022

Lee Schwartzberg, MD, FACP, explains how Ki-67 is measured and used to inform management strategies for HR+ breast cancer at his clinical practice.

The Evolution of Early-Stage HR+ Breast Cancer Management

August 5th 2022

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, discuss how the management of early-stage HR+ breast cancer has changed over time.

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Frontline Combination Strategies in HR+/HER2- BC

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

July 4th 2022

Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

July 4th 2022

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

June 27th 2022

Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.